FullHope Biomedical Co (ROCO:7773) Marketable Securities: NT$318.02 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7773 FullHope Biomedical Co Ltd ROCO:7773
12 GF Score
Price NT$26.25
! 1 Warning Sign
View Full Analysis

What is FullHope Biomedical Co Marketable Securities?

FullHope Biomedical Co ROCO:7773 +0.19% 12 Marketable Securities is NT$318.02 Mil as of Dec. 2025. GuruFocus rates ROCO:7773 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. FullHope Biomedical Co's Marketable Securities for the quarter that ended in Dec. 2025 was NT$318.02 Mil.

FullHope Biomedical Co's annual Marketable Securities increased from Dec. 2023 (NT$506.95 Mil) to Dec. 2024 (NT$515.42 Mil) but then declined from Dec. 2024 (NT$515.42 Mil) to Dec. 2025 (NT$318.02 Mil).

FullHope Biomedical Co  (ROCO:7773) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

FullHope Biomedical Co Marketable Securities Related Terms

FullHope Biomedical Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for FullHope Biomedical Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FullHope Biomedical Co Marketable Securities Chart

FullHope Biomedical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
65.74 44.25 506.95 515.42 318.02

FullHope Biomedical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial 506.95 487.25 515.42 519.92 318.02
ROCO:7773
12GF Score
FullHope Biomedical Co Ltd ROCO:7773
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

FullHope Biomedical Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$318.02 Mil mean?
FullHope Biomedical Co (ROCO:7773) has a Marketable Securities of NT$318.02 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on FullHope Biomedical Co and its competitors.
Is FullHope Biomedical Co's Marketable Securities too high?
FullHope Biomedical Co's current Marketable Securities is NT$318.02 Mil. Overall, FullHope Biomedical Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's Marketable Securities compare to VRTX and REGN?
FullHope Biomedical Co's Marketable Securities of NT$318.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on FullHope Biomedical Co and its competitors. FullHope Biomedical Co's current Marketable Securities is NT$318.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current Marketable Securities of NT$318.02 Mil. The current Marketable Securities is NT$318.02 Mil. FullHope Biomedical Co's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current Marketable Securities is NT$318.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FullHope Biomedical Co Business Description

Address Lane 609, Sector. 5, Chongxin Road, 10th Floor, No. 10, Sanchong District, New Taipei City, TWN
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
12GF Score

Get the complete analysis for ROCO:7773

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.25
Price